Hospitalogy December 5, 2024
Despite being in the news regularly, few people in the industry truly understand the nuances of the 340B Drug Pricing Program. But this program is becoming critical to the economics of stakeholders across the healthcare ecosystem from drug manufacturers and providers to health systems and pharmacy benefit manager (PBM) owned contract pharmacies.
To help dissect this topic, I worked with LRVHealth Managing Partner Josh Flum, Senior Associate Lise Courtney D’Amico, and VP of Strategic Engagement Karen Au Yeung. If you aren’t familiar with LRVHealth, it is a strategic venture capital platform with a unique investing model in healthcare. By partnering with leading health systems and payers as strategic limited partners, the company has built a powerful network which collectively touches...
Today's Sponsors
Today's Sponsor